Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001542 | 0.84 | TDP1 (0.37) | CYP1A2HIPK2ACHETDP1AXL | |
| SCHEMBL289039 | 0.84 | GAA (0.43) | CYP1A2HIPK2ACHECYP2A6TDP1 | |
| SCHEMBL18103466 | 0.84 | GAA (0.43) | CYP1A2HIPK2ACHETDP1AXL | |
| SCHEMBL12245721 | 0.84 | AXL (0.60) | CYP1A2HIPK2ACHETDP1AXL | |
| SCHEMBL13049641 | 0.84 | TDP1 (0.37) | CYP1A2HIPK2ACHECYP2A6TDP1 | |
| SCHEMBL24724775 | 0.84 | AXL (0.55) | CYP1A2HIPK2ACHECYP2A6TDP1 | |
| SCHEMBL14589052 | 0.84 | AXL (0.55) | CYP1A2ACHETDP1AXLSIRT3 | |
| SCHEMBL12136286 | 0.84 | TDO2 (0.38) | CYP1A2HIPK2ACHETDP1AXL | |
| SCHEMBL19662991 | 0.84 | TDO2 (0.38) | CYP1A2HIPK2ACHETDP1AXL | |
| SCHEMBL17571743 | 0.84 | AXL (0.60) | CYP1A2HIPK2TDP1AXLSIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-3082867-B1 | ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS | INTERVET INT BV (NL) | 2024-01-17 | — | — | EP | disclosed |
| EP-4076447-B1 | PARASITE CONTROL IN RUMINANTS | INTERVET INT BV (NL) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306168-A2 | ISOXAZOLINE COMPOSITIONS AND USE THEREOF IN THE PREVENTION OR TREATMENT OF PARASITE INFESTATIONS IN ANIMALS | Intervet International B.V. (NL) | 2024-01-17 | — | — | EP | disclosed |
| US-11858904-B2 | Process for preparing large size isoxazoline particles | INTERVET INC. (JE) | 2024-01-02 | — | — | US | disclosed |
| US-11858904-B2 | Process for preparing large size isoxazoline particles | INTERVET INC. (JE) | 2024-01-02 | — | — | US | disclosed |
| US-20230320981-A1 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | INTERVET INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230310386-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTERVET INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11712416-B2 | Solid oral pharmaceutical compositions for isoxazoline compounds | INTERVET INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2008142454-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| US-20080265755-A1 | Biscarbazol-9-Yl-Substituted Triarylamine-Containing Polymers and Electronic Devices | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1881349-A1 | COMPOSITION FOR ANISOTROPIC DYE FILM, ANISOTROPIC DYE FILM, AND POLARIZING DEVICE | Mitsubishi Chemical Corporation (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20080011353-A1 | Triarylamine Containing Polymers and Electronic Devices | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080011353-A1 | Triarylamine Containing Polymers and Electronic Devices | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1857521-A1 | ORGANIC ELECTRIC FIELD LIGHT EMITTING ELEMENT AND PRODUCTION THEREFOR | Mitsubishi Chemical Corporation (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1576032-B1 | TRICYCLIC ARYLAMINE MONOMER AND POLYMERS AND DEVICES THEREOF | DOW GLOBAL TECHNOLOGIES INC (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007107356-A1 | METHOD FOR PREPARING DOPED ORGANIC SEMICONDUCTOR MATERIALS AND FORMULATION UTILIZED THEREIN | NOVALED AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070141388-A1 | Electroluminescent device containing a butadiene derivative | EASTMAN KODAK COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070141388-A1 | Electroluminescent device containing a butadiene derivative | EASTMAN KODAK COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858904-B2 | Process for preparing large size isoxazoline particles | PDE8A, RPS4X, MRPS27 | CYP1A2 83/4885HIPK2 2138/4885ACHE 608/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | CYP1A2 4149/4885HIPK2 631/4885ACHE 4596/4885 |
| US-20230310386-A1 | INJECTABLE PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CYP3A7, PDE8A, CYP4X1 | CYP1A2 202/4885HIPK2 2345/4885ACHE 801/4885 |
| US-11712416-B2 | Solid oral pharmaceutical compositions for isoxazoline compounds | CYP3A7, SI, CYP2A7 | CYP1A2 17/4885HIPK2 3593/4885ACHE 255/4885 |
| US-20230320981-A1 | SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS | CYP3A7, SI, CYP2A7 | CYP1A2 17/4885HIPK2 3593/4885ACHE 255/4885 |
| US-20080265755-A1 | Biscarbazol-9-Yl-Substituted Triarylamine-Containing Polymers and Electronic Devices | PYM1, KCNMB4, BRD9 | CYP1A2 516/4885HIPK2 4542/4885ACHE 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.